Stoke (STOK) Q3 2026 Earnings Call Transcript
Dravet syndrome trial enrollment exceeded targets with zero discontinuations.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
